Item 1.01. Entry into a Material Definitive Agreement.
The disclosure contained in Item 2.03 is incorporated by reference in this Item 1.01
Financial Obligation Form 8 K
Keen Vision Acquisition Corporation on 6ix
Earlier from Keen Vision Acquisition
Later from Keen Vision Acquisition
- Medera to Present Late-Breaking Phase 1/2a Clinical Trial Results at Heart Failure 2025 Congress
- Medera Showcased Positive Interim Data From First-in-Human Gene Therapy Trial for HFpEF in Late-Breaking Presentation at Heart Failure 2025 Congress
- Medera’s Novoheart Enters New Collaboration to Develop Human Mini-Heart Models Aimed at Transforming Treatment for Hypoplastic Left Heart Syndrome
- Medera and University of Kansas Medical Center Announce First Patient Treated in Pioneering Gene Therapy Trial for Duchenne Muscular Dystrophy Associated Cardiomyopathy
Follow Keen Vision Acquisition into a list and get an email when it puts out news.
Follow Keen Vision Acquisition